vTv Therapeutics (NASDAQ:VTVT) Upgraded at Wall Street Zen

vTv Therapeutics (NASDAQ:VTVT) was upgraded by equities researchers at Wall Street Zen to a “sell” rating in a research report issued on Saturday.

Several other equities analysts have also recently commented on the stock. HC Wainwright reissued a “buy” rating and set a $47.00 target price (up previously from $36.00) on shares of vTv Therapeutics in a research note on Friday, December 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of vTv Therapeutics in a report on Monday. Finally, BTIG Research assumed coverage on vTv Therapeutics in a report on Wednesday, November 19th. They set a “buy” rating and a $40.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $43.50.

vTv Therapeutics Price Performance

Shares of vTv Therapeutics stock opened at $37.91 on Friday. The business’s fifty day moving average price is $28.68 and its two-hundred day moving average price is $21.50. The company has a market capitalization of $149.37 million, a P/E ratio of -11.42 and a beta of 0.50. vTv Therapeutics has a 1-year low of $13.15 and a 1-year high of $38.46.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.11).

Institutional Inflows and Outflows

An institutional investor recently raised its position in vTv Therapeutics stock. Baker BROS. Advisors LP raised its stake in vTv Therapeutics Inc. (NASDAQ:VTVT) by 52.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 148,314 shares of the biotechnology company’s stock after buying an additional 51,000 shares during the period. Baker BROS. Advisors LP owned approximately 3.77% of vTv Therapeutics worth $3,463,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.